



Appointment of an Independent Non-Executive Director

Sheffield, UK, 29th January 2020: Rinri Therapeutics (“Rinri”), a biotechnology company developing a novel cell-based therapy to restore hearing, backed by Boehringer Ingelheim Venture Fund, UCB Ventures, and BioCity, is pleased to announce that Dr. Natalie Mount will join the Board as an Independent Non-Executive Director with effect from 6th January 2020.

Dr. Mount brings over 20 years of experience in drug development, including most recently, more than 10 years of experience specialising in the development of cell and gene therapies covering translational, manufacturing, regulatory and clinical disciplines.

Natalie is currently the CEO of Adaptate Biotherapeutics Ltd. focused on developing therapeutic antibodies to drug targets to modulate the activity of gamma delta T cells. Previously, Natalie was Chief Scientific Officer of GammaDelta Therapeutics Ltd. which targeted gamma delta T-cell therapies for use in immunotherapy and was one of the founding team at the Cell and Gene Therapy Catapult serving as its Chief Clinical Officer advising academics and small companies developing advanced therapies. Natalie’s prior experience also includes 16 years at Pfizer, leading development activities across various therapeutic areas, including cell-based therapies in the Regenerative Medicine Unit. Natalie has a first-class degree in Natural Sciences from the University of Cambridge and a Ph.D. from University College, London.

Simon Chandler, CEO of Rinri said, “I am delighted to welcome Natalie to Rinri as she brings unique and wide-ranging expertise in ATMP development to our Board. In particular, her work in the translation of candidate cell therapies from the early academic stages through to GMP manufacturing and clinical development, will significantly benefit Rinri in achieving our ambition to improve the lives of patients with hearing loss.”

Commenting on her appointment, Natalie Mount said, “I am thrilled to be joining the Board at Rinri at a very exciting time in the development of this unique regenerative cell therapy. I look forward to using my experience to assist in bringing this innovative product towards the clinic.”

Erica Whitaker, Chair of Rinri said, “Natalie brings valuable experience and expertise, and we are very pleased to welcome her to the Rinri team.”

-End-

About Rinri Therapeutics

Rinri Therapeutics is a private biotechnology company developing advanced stem cell-based therapeutics to restore hearing. The company’s pioneering technology seeks to reverse neuropathic sensorineural hearing loss (SNHL) through the repair of the damaged cytoarchitecture in the inner ear. SNHL is estimated to affect 64 million patients in the US and 34 million in Europe. There are currently no pharmacological treatment options for SNHL patients. Rinri is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield. Rinri was founded in late-

2018 and is headquartered in Sheffield, UK. For more information, please visit: www.rinri-therapeutics.com

About Boehringer Ingelheim Venture Fund

Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in ground-breaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF's focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, in regenerative medicine or infectious diseases. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy as well as Digital Health. BIVF takes an active role with its portfolio companies – delivering significant added value through its own extensive drug discovery, scientific and managerial expertise. BIVF has €250 million under management and currently supervises a portfolio of 25 companies. For more information, please visit www.boehringer-ingelheim-venture.com

About UCB Ventures

UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. UCB Ventures invests in innovative therapeutics and technology platforms that are early stage and higher risk, in areas adjacent to or even beyond UCB's therapeutic focus on neurology/neurodegenerative diseases, immunology and muscular-skeletal/bone health. UCB Ventures takes an active role in its portfolio companies, contributing expertise in drug discovery, development and operations. Visit www.UCBVentures.com to learn more.

About BioCity

Home to more than 200 pioneering Life Science and Healthcare companies, BioCity is an ambitious business incubator dedicated to helping small businesses tackle global health & environmental challenges. Not the typical business incubator, BioCity takes a holistic approach to business support. It offers an in-house accelerator programme, investment platform, flexible lab and office space, UK wide network of mentors and specialised equipment, all housed within the various BioCity business locations. Founded in 2002 BioCity operates at sites in Nottingham, Glasgow, Cheshire, Aberdeen and Newcastle. The company has made a total of 26 investments in early-stage companies and has delivered healthy growth in portfolio valuation. Funds are deployed from their own cash reserves and from a joint venture vehicle with AstraZeneca which BioCity manages. In 2017, BioCity was identified as one of Europe's fastest-growing companies in the Financial Times' FT 1000 report. The BioCity model of 'support from inception to incorporation' initially challenged the industry standard but quickly became the industry leader due to the unprecedented survival rates of BioCity based businesses. For more information visit <https://biocity.co.uk/about>

About the University of Sheffield

With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world's leading universities. A member of the UK's prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines. Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in. Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education. Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant

contributions in their chosen fields. Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, GlaxoSmithKline, Siemens, and Airbus, as well as many UK and overseas government agencies and charitable foundations. To find out more, visit: <http://www.sheffield.ac.uk>

For more information please contact:

Rinri Therapeutics Ltd.

Simon Chandler, CEO

admin@rinri-therapeutics.com

T: +44 [0] 114 222 4330